Written by Private MD Labs Medical Writing Team • Last Updated: September 8, 2025
Light Chain Deposition Disease (LCDD) is a rare disorder where abnormal monoclonal light chains are deposited in various organs throughout the body, potentially causing kidney dysfunction, heart problems, and damage to other vital organs. Early detection through specialized blood testing is crucial for proper management and treatment.
This comprehensive test measures both kappa and lambda light chain levels and calculates their ratio. An abnormal kappa/lambda ratio is a key diagnostic marker for Light Chain Deposition Disease, as the condition typically involves an excess of one type of light chain. The reflex to immunofixation provides additional confirmation when abnormal results are detected.
Unlike many conditions that require tissue biopsies for definitive diagnosis, LCDD can be effectively detected and monitored through specific blood tests that measure light chain proteins. These tests can identify abnormal levels and ratios of light chains that are characteristic of the disease.
This test directly measures surface light chain levels in the blood. Since Light Chain Deposition Disease is caused by the deposition of monoclonal light chains in organs, elevated levels of these proteins can indicate the presence of this rare disease and help guide treatment decisions.
Light Chain Deposition Disease can cause progressive organ damage, particularly affecting the kidneys, heart, and liver. Early detection through blood testing allows for prompt treatment initiation, which may help slow disease progression and preserve organ function.
The information here is for educational purposes only and is not a substitute for professional medical advice. Always consult with a healthcare provider for diagnosis and treatment.